quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:15:09·966d
INSIDERFiling
Focus Financial Partners Inc. logo

SEC Form 4: Stone Point Capital Llc converted options into 8,250,165 shares and returned $850,595,675 worth of shares to the company (16,048,975 units at $53.00)

FOCS· Focus Financial Partners Inc.
Finance
Original source

Companies

  • FOCS
    Focus Financial Partners Inc.
    Finance

Recent analyst ratings

  • Mar 2UpdateKeefe Bruyette$55.00
  • Feb 21UpdateRBC Capital Mkts$53.00
  • Feb 21UpdateTruist$53.00
  • Feb 17UpdateRaymond James-
  • Feb 17UpdateOppenheimer-
  • Feb 15UpdateMorgan Stanley$53.00

Related

  • 13D/G804d
    SEC Form SC 13G/A filed by Focus Financial Partners Inc. (Amendment)
  • SEC955d
    SEC Form 15-12G filed by Focus Financial Partners Inc.
  • INSIDER965d
    SEC Form 4 filed by Adolf Ruediger
  • INSIDER965d
    SEC Form 4: Shanahan James converted options into 953,737 shares and returned $50,548,061 worth of shares to the company (953,737 units at $53.00)
  • INSIDER965d
    SEC Form 4: Adolf Ruediger converted options into 2,379,777 shares and returned $126,128,181 worth of shares to the company (2,379,777 units at $53.00)
  • INSIDER965d
    SEC Form 4: Morganroth Greg S. converted options into 20,311 shares and returned $1,076,483 worth of shares to the company (20,311 units at $53.00)
  • INSIDER965d
    SEC Form 4: Lemieux George converted options into 9,611 shares and returned $509,383 worth of shares to the company (9,611 units at $53.00)
  • INSIDER965d
    SEC Form 4: Mcgranahan John Russell converted options into 413,124 shares and returned $21,948,572 worth of shares to the company (414,124 units at $53.00), closing all direct ownership in the company
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022